Published Date: 31 Dec 2024
3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone
Read Full NewsNew UBC Okanagan research shows that exercise can do more than improve the strength and cardiovascular endurance of women who have survived breast cancer.
UCLA scientists, together with a team of international collaborators, have identified a promising new treatment strategy that can detect, kill and reprogram aggressive, treatment-resistant tumors like osteosarcomas and glioblastoma.
A research team led by Cancer Center at Illinois (CCIL) member Hua Wang has published new research detailing a new mRNA cancer vaccine platform. The study introduces an immune cell homing hydrogel-based platform designed ...
1.
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
2.
New research uncovers link between cancer pathway and blood-retina barrier function
3.
In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.
4.
A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.
5.
According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.
1.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
2.
Genetic Screening: A Game Changer in Cancer Prevention
3.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
The Basics of M.C.V Normal Range for Better Health Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation